Why the study?
Diagnostic and therapeutic tools significantly impact ACS morbidity and mortality, but data regarding ACS performance measures are scarce in Brazil.
Does higher adherence to evidence-based therapies (measured by a performance score) reduce in-hospital mortality in patients with acute coronary syndromes?
Does higher adherence to evidence-based therapies (measured by a performance score) reduce in-hospital mortality in patients with acute coronary syndromes?
Higher adherence to evidence-based therapies for ACS, as measured by a performance score, is independently associated with lower in-hospital mortality in Brazil.
Answers are grounded in this paper and cite their sources.
Supports performance scores for ACS quality monitoring in Brazil; hypothesis-generating for whether adherence interventions reduce mortality.
AIMS: Diagnostic and therapeutic tools have a significant impact on morbidity and mortality associated with acute coronary syndromes (ACS). Data about ACS performance measures are scarce in Brazil, and improving its collection is an objective of the Brazilian Registry in Acute Coronary syndromEs (BRACE). METHODS AND RESULTS: The BRACE is a cross-sectional, observational epidemiological registry of ACS patients. Stratified 'cluster sampling' methodology was adopted to obtain a representative picture of ACS. A performance score (PS) varying from 0 to 100 was developed to compare studied parameters. Performance measures alone and the PS were compared between institutions, and the relationship between the PS and outcomes was evaluated. A total of 1150 patients, median age 63 years, 64% male, from 72 hospitals were included in the registry. The mean PS for the overall population was 65.9% ± 20.1%. Teaching institutions had a significantly higher PS (71.4% ± 16.9%) compared with non-teaching hospitals (63.4% ± 21%; P < 0.001). Overall in-hospital mortality was 5.2%, and the variables that correlated independently with in-hospital mortality included: PS-per point increase (OR = 0.97, 95% CI 0.95-0.98, P < 0.001), age-per year (OR = 1.06, 95% CI 1.03-1.09, P < 0.001), chronic kidney disease (OR = 3.12, 95% CI 1.08-9.00, P = 0.036), and prior angioplasty (OR = 0.25, 95% CI 0.07-0.84, P = 0.025). CONCLUSIONS: In BRACE, the adoption of evidence-based therapies for ACS, as measured by the performance score, was independently associated with lower in-hospital mortality. The use of diagnostic tools and therapeutic approaches for the management of ACS is less than ideal in Brazil, with high variability especially among different regions of the country.
No takes yet. Share an insight, caveat, or question.
Franken et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: